| SM Hírek : Renovis Announces Initiation of Phase Ia Clinical Study with Investigational Medicine for Multiple Sclerosis |
Renovis Announces Initiation of Phase Ia Clinical Study with Investigational Medicine for Multiple Sclerosis
2005.02.17. 01:05
SOUTH SAN FRANCISCO, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Renovis, Inc. (Nasdaq: RNVS - News) announced today the initiation of a Phase Ia clinical trial for REN-850, an investigational oral small molecule that is being targeted for the treatment of multiple sclerosis (MS). The objective of this trial is to assess the safety, tolerability and pharmacokinetics of escalating single doses of REN-850 in healthy volunteers. Approximately 45 subjects are planned to participate in the study.
Monday February 14,
http://biz.yahoo.com/prnews/050214/nym296_1.html
"The Phase Ia trial with REN-850 represents the first step towards establishing safety and tolerability in humans," said Randall Moreadith, MD, PhD, Chief Medical Officer of Renovis. "Successful completion of this trial will provide valuable data to support a Phase Ib study of escalating multiple doses of REN-850 in MS patients. The Phase Ib study is currently planned to start enrolling subjects in the fourth quarter of 2005."
REN-850 acts by inhibiting leukocyte trafficking and preclinical studies have shown that REN-850 modulates the cell migration driven by multiple chemokine receptors. These studies have also shown that oral administration of REN-850 significantly reduces severity of outcomes in multiple in vivo models of MS and rheumatoid arthritis (RA).
"Preclinical data suggest that targeting the actions of multiple chemokine receptors may represent a more effective approach to the treatment of MS and other autoimmune diseases than drugs that are more narrowly targeted," said Tito Serafini, PhD, Vice President of Discovery Research of Renovis.
About Renovis
Renovis is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. Our most advanced product candidate is CEROVIVE (NXY-059), an intravenous drug for acute ischemic stroke that is in Phase III clinical trials with our exclusive licensee, AstraZeneca AB. We are independently developing REN-1654, an oral drug for neuropathic pain in Phase II clinical trials and REN-850, an oral drug for multiple sclerosis in Phase I clinical trials. Our research and development programs focus on major medical needs in the areas of neuroprotection, pain and neuroinflammatory diseases.
For additional information about the company, please visit http://www.renovis.com.
CEROVIVE (NXY-059) is a registered trademark of the AstraZeneca group of companies. All other product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.
| 
AJÁNLOM AZ OLDALT
Friss bejegyzések
Friss hozzászólások
Archívum
